CSI Market
Sign In | Register

Enanta Pharmaceuticals Inc (ENTA) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access ENTA Annual Cash Flow →
A period-by-period view of cash flow from Enanta Pharmaceuticals Inc to Jun 30 2025 helps clarify how Jun 30 2026's cash position has changed over time.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
9 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income-44.53
Depreciation & amortization3.62
Amortization of Other Assets4.80
Increase (Decrease) in Deferred Revenue0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets, Total0.00
Share-based Compensation11.24
Income (Loss) from Equity Method Investments0.00
Paid-in-Kind Interest0.00
Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net-
Increase Decrease In Fair Value Of Unhedged Derivative Instruments-
Increase Decrease In Operating Lease Right Of Use Assets1.11
Fair Value Adjustment Nonconvertible Preferred Stock-
Non Cash Interest Expense Associated With The Sale Of Future Royalties0.93
Non Cash Interest Associated With The Sale Of Future Royalties-
Increase Decrease In Operating Lease Liability-1.37
Income taxes0.00
Losses/ -gains on Investments net0.00
Accounts Receivable-0.35
Increase (Decrease) in Accounts Payable1.34
Increase (Decrease) in Accrued Liabilities-2.57
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-1.01
Other Working Capital0.04
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-1.42
Discontinued operations0.00
Net Cash flow from Operating Activities-28.83
Investing Activities
Capital Expenditures-0.17
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Available-for-sale Securities194.90
Payments to Acquire Marketable Securities-216.08
Real Estate Investments0.00
Increase (Decrease) in Restricted Cash0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-21.35
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock70.63
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net-0.40
Other net-18.93
Proceeds From Payments For Longterm Capital Lease Obligations-
Proceeds From Stock Options And Warrants Exercised-
Proceeds From Sale Of Future Royalties-
Payments On Royalty Sale Liability Net Of Imputed Interest-12.90
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities51.30
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-28.99
Total Cash Flow1.12
4 historic quarters locked

Sign in to unlock the full Enanta Pharmaceuticals Inc cash flow history.

Sign In Create Free Account

About Enanta Pharmaceuticals Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-26-345719

Figures are derived from filed reports and may be restated. Historical data is subject to revision.